STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
NCT00006052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2014-01-31
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia.
PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
Conditions
Interventions
- DRUG
-
imatinib mesylate
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ilana Monteleone · Novartis Pharmaceuticals
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-06-30
- Primary Completion
- 2003-06-30
Countries
- United States
Study Locations
More Related Trials
-
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
NCT00006343 ·Status: COMPLETED ·Phase: PHASE3
-
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
NCT00015860 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
NCT00171158 ·Status: COMPLETED ·Phase: PHASE2
-
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase
NCT00514969 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
NCT00028847 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00022490 ·Status: TERMINATED ·Phase: PHASE2
-
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00039377 ·Status: COMPLETED ·Phase: PHASE2
-
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
NCT00511303 ·Status: COMPLETED ·Phase: PHASE2
-
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00012259 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
NCT05947344 ·Status: RECRUITING ·Phase: PHASE1
-
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
NCT00038649 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00041990 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042016 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042003 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years
NCT00219752 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
NCT00333840 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation
NCT00219726 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
NCT01419496 ·Status: COMPLETED
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916 ·Status: COMPLETED ·Phase: PHASE2
-
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
NCT00004009 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
NCT00362466 ·Status: TERMINATED ·Phase: PHASE3
-
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
NCT00459212 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
NCT00171899 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
NCT00497991 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
NCT00349518 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3